Call us today for help! (214) 295-5011
In April 2014, Personal Genome Diagnostics (PGDx) launched a new test to detect and treat cancerous tumors. PGDx was founded by Luis Diaz, MD, and Victor Velculescu, MD, PhD, both internationally recognized leaders in cancer genomics at Johns Hopkins University. PGDx has been funded primarily through revenues from the cancer genome analysis services it provides, …
Eisai, and its subsidiary Morphotek, discovered and have developed an investigational monoclonal antibody amatuximab. This drug “has a high affinity and specificity for mesothelin, a protein which is overexpressed in people with malignant mesothelioma.” The European Commission has granted this antibody an orphan drug designation (ODD). This designation is for medicines developed for the diagnosis, …
After an inspection of a science building revealed asbestos dust, mercury vapor, and lead paint, San Francisco State University closed the building for the entire 2014 spring semester. This requires finding classrooms, labs, and offices for more than 2,500 students and staff. Les Wong, president of the university, stated, “The University is working with health …
On January 16th, the United States Senate designated the first week of April 2014 as National Asbestos Awareness Week. As a part of this, the senate urged the Surgeon General to warn and educate people about asbestos exposure and its hazards to health. This began as National Asbestos Awareness Day but was changed in 2005 …
U.S. Navy veterans serving from World War II through Vietnam faced a toxic threat from the asbestos aboard their own ships. Many decades later that exposure surfaced in the form of asbestos-related diseases. Of the 2,500 to 3,000 Americans diagnosed annually with malignant mesothelioma, a significant percentage of those individuals served in the U.S. Navy. Still …
